Transurethral resection of the prostate — wire-loop electrocautery shaving of obstructing adenoma to restore the urethral channel
Benign prostatic hyperplasia (BPH) affects roughly 50% of men over 50 and up to 90% by their 80s. When lower urinary tract symptoms (LUTS) become bothersome or medical therapy (alpha-blockers, 5-alpha-reductase inhibitors) fails, transurethral resection of the prostate — the historical gold-standard surgical treatment — is considered. Careful patient selection based on symptom severity, prostate size, and flow dynamics determines candidacy and expected outcome.
The International Prostate Symptom Score (IPSS) — seven questions on incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia, each 0–5 — stratifies patients as mild (0–7), moderate (8–19), or severe (20–35). A eighth quality-of-life question captures bother.
Absolute indications for surgery regardless of symptom score include refractory urinary retention, recurrent UTIs, bladder stones, recurrent gross hematuria of prostatic origin, renal insufficiency from obstruction, and large bladder diverticula. Relative indications are moderate-to-severe LUTS (IPSS ≥8) with a measurably bothered quality of life that has failed or is intolerant of medical therapy (alpha-1 blockers such as tamsulosin, 5-alpha-reductase inhibitors such as finasteride).
Uroflowmetry adds an objective functional axis: a maximum flow rate (Qmax) below 10–12 mL/s with a voided volume >150 mL strongly suggests bladder outlet obstruction, while post-void residual (PVR) >100–150 mL indicates incomplete emptying and supports surgical intervention.
Transrectal ultrasound (TRUS) or MRI estimates prostate volume using the prolate ellipsoid formula (length × width × height × 0.52). This single number is the pivotal decision point for technique selection:
• 30–80 mL: classic monopolar or bipolar TURP is the workhorse — the size range in which resection time (and glycine/saline absorption risk) remains manageable • <30 mL: bladder neck incision (TUIP) may suffice with lower morbidity • >80–100 mL: holmium laser enucleation (HoLEP), simple open/robotic prostatectomy, or staged/longer bipolar resection is often preferred, since resection time for very large glands raises TUR syndrome and bleeding risk substantially
Cystoscopy prior to resection confirms gland configuration (trilobar vs bilobar), bladder capacity, presence of stones or diverticula, and any urethral stricture that would need dilation before scope passage. PSA and digital rectal exam screen for coexisting prostate cancer, which does not exclude TURP but changes counseling.
TURP remains the reference standard against which every newer BPH surgical technology (laser enucleation, vaporization, prostatic urethral lift, water vapor therapy) is benchmarked in randomized trials — a testament to a technique essentially unchanged in principle since the 1930s.
Anticoagulants and antiplatelet agents are reviewed and bridged or held per cardiology guidance — bleeding risk is a central concern in a vascular organ resected under electrocautery. Urine culture is checked and treated if positive, since instrumenting an infected urinary tract risks urosepsis. Baseline renal function, hemoglobin, and coagulation studies are obtained.
Patients are counseled on realistic expected outcomes (see Stage 5) and the specific risk profile of the chosen energy modality — bipolar in saline versus monopolar in glycine — which materially affects the risk of dilutional hyponatremia (TUR syndrome).
The resectoscope is a rigid endoscope with a working element that carries the cutting loop, a telescope providing direct visualization, and an outer sheath through which irrigation fluid continuously flows in and out. The choice between monopolar and bipolar energy dictates the required irrigant — a decision with direct patient-safety consequences.
After urethral lubrication (and dilation if needed), the resectoscope sheath with obturator is passed under direct or blind guidance through the fossa navicularis, bulbar and membranous urethra, past the external sphincter, into the prostatic urethra and bladder. The obturator is removed and the working element with telescope and loop electrode inserted.
A full diagnostic sweep is performed before resection begins: bladder mucosa and trigone are inspected, ureteric orifices identified (to avoid inadvertent resection near them), and the prostatic urethra surveyed end to end. Three landmarks anchor the entire procedure —
• Bladder neck: proximal limit, where resection typically begins • Verumontanum: a mound on the posterior urethral wall marking the seminal colliculus — the single most important distal landmark • External urethral sphincter: lies just distal to the verumontanum; resection distal to the verumontanum risks sphincter injury and incontinence
Classic monopolar TURP passes current from the loop electrode through the patient to a remote grounding pad, requiring a non-conductive, electrolyte-free irrigant (1.5% glycine, or less commonly sorbitol/mannitol) so the current is not dissipated through the irrigation fluid itself. This hypotonic, electrolyte-free irrigant is the direct cause of TUR syndrome when absorbed in volume through open venous sinuses.
Bipolar TURP (introduced clinically in the early 2000s) confines current flow between two electrodes on the loop itself (active and return elements are both on the instrument), so normal isotonic saline can be used as irrigant. Saline is physiologically inert if absorbed, effectively eliminating the electrolyte-dilution mechanism of TUR syndrome, and permits longer, more confident resection of larger glands.
The shift from monopolar to bipolar (plasma-kinetic/vaporization) technology over the last two decades is the single biggest safety advance in TURP since its invention — cutting symptomatic TUR syndrome from a historical 2% down to a rate that is now vanishingly small.
A continuous-flow sheath has separate inflow and outflow channels so irrigant is constantly exchanged, keeping the operative field clear of blood and resected chips and preventing dangerous overdistension of the bladder. Irrigant is typically hung 60–70 cm above the patient to balance visibility against absorption pressure — too high raises intravesical pressure and promotes fluid intravasation through opened venous sinuses.
Fluid deficit (irrigant instilled minus irrigant collected) is tracked throughout the case as an indirect proxy for absorption; with monopolar glycine, a deficit exceeding roughly 1000 mL is a trigger to expedite completion of resection due to rising TUR syndrome risk.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Monopolar (classic) | Current: loop → tissue → body → grounding pad | Requires electrolyte-free irrigant (1.5% glycine) | Lower equipment cost; long track record |
| Bipolar (plasma-kinetic) | Current: active ↔ return, both on loop tip | Isotonic saline irrigant — no dilutional risk | ~0% TUR syndrome; longer safe resection time |
| TUR syndrome risk | Dilutional hyponatremia from irrigant absorption | Monopolar: ~2% (historically up to 5–7% in long cases) | Bipolar: near 0% |
| Typical resection time limit | Guideline caution point for safety | Monopolar: ideally <60–90 min | Bipolar: less time-restricted |
Resection proceeds as a deliberate, systematic dismantling of obstructing tissue rather than a random carving process. The wire loop is drawn from the bladder neck toward the surgeon (proximal to distal) under continuous electrocautery, shaving overlapping strips ("chips") of adenoma tissue until a wide-open channel is achieved from bladder neck to just proximal to the verumontanum.
A standard sequence minimizes bleeding and disorientation:
1. Bladder neck / median lobe: the 5, 6, 7 o'clock and 12 o'clock bladder-neck tissue is opened first to establish a proximal reference channel and control the prominent venous plexus at the bladder neck early 2. Right and left lateral lobes: resected systematically in quadrants, working circumferentially, always keeping the loop under direct vision and never cutting on the inward (toward-surgeon-blind) stroke 3. Apical tissue: the most delicate portion, resected last and with the greatest caution, working just proximal to the verumontanum to leave a cuff of tissue protecting the external sphincter 4. Final channel check: telescope is passed end-to-end to confirm a wide, smooth, symmetric channel with no residual overhanging tissue ("floating" tags) that could later obstruct or bleed
The energized wire loop is extended beyond the tissue to be cut and drawn back toward the resectoscope sheath (never pushed forward blindly) while high-frequency current vaporizes a thin path of tissue, releasing the chip which floats free in the irrigant. Cutting waveform (continuous, lower-voltage) is used for the cutting stroke; coagulation waveform (pulsed, higher peak voltage) for hemostasis, described in Stage 4.
Chip size is deliberately kept small and uniform (each chip typically 1–3 g) — smaller chips are more easily evacuated, allow better visualization of the resection bed, and reduce the chance of an overly deep cut into the surgical capsule, which risks capsular perforation and extravasation.
Depth control is critical: resection is carried down to but not through the surgical capsule (the compressed peripheral zone/true capsule of the prostate) — visible as a pale, glistening, circular fibrous ring with characteristic capsular fibers. Cutting through the capsule risks perforation, extravasation of irrigant into the retropubic or peritoneal space, and injury to periprostatic structures.
Two structures are deliberately spared throughout resection:
• Verumontanum: never resected; it marks the point beyond which lies the external sphincter mechanism. Surgeons routinely leave a small collar of tissue just proximal to it • External urethral sphincter: preserving tissue distal to the verumontanum protects the striated sphincter responsible for voluntary urinary control — injury here is the principal mechanism of post-TURP stress incontinence
The internal (bladder neck) sphincter is intentionally resected/incised as part of the procedure — this is expected and is actually part of why retrograde ejaculation occurs in the large majority of patients (discussed in Stage 5), since semen preferentially flows backward into the now-open bladder neck during ejaculation rather than forward.
The prostate is a highly vascular organ, and resection inevitably opens numerous small arterioles and the periprostatic venous plexus. Meticulous, continuous hemostasis throughout — not just at the end — is what keeps the field visible and the patient safe; uncontrolled bleeding is the leading cause of intraoperative TURP complications and postoperative clot retention.
As each chip is resected and the underlying tissue bed exposed, bleeding vessels are immediately identified and coagulated before proceeding — bleeding obscures the field and makes subsequent cuts less precise, so hemostasis is interleaved with cutting rather than deferred. The same loop electrode (held just above the bleeding point without cutting) or a dedicated roller-ball/roller-barrel electrode is switched to coagulation waveform: pulsed, higher-voltage current that denatures vessel wall protein and seals the lumen without the continuous vaporizing action of the cutting waveform.
Venous sinus bleeding at the bladder neck and capsular arterial bleeders at the 4–5 and 7–8 o'clock positions (site of the prostatic vascular pedicles) are the most common and most important bleeding points requiring deliberate attention.
Resected chips accumulate in the bladder throughout the case and must be evacuated before the procedure ends — retained chips can obstruct the catheter postoperatively and cause clot/debris retention. Two classic methods:
• Ellik evacuator: a bulb-and-container device that alternately irrigates and aspirates the bladder through the sheath, flushing chips out in bulk • Toomey syringe: a large (~50–60 mL) syringe used to manually irrigate and aspirate chips through the sheath
All retrieved tissue is sent for histopathology — routine practice, since incidental prostate adenocarcinoma is identified in a meaningful minority (historically ~8–10%) of TURP specimens even when preoperative PSA and DRE were unremarkable.
A final cystoscopic inspection confirms a dry field before the case ends: any persistent bleeding point at this stage is coagulated definitively, since postoperative bleeding requiring return to the OR is far more morbid than a few extra minutes of intraoperative coagulation.
Venous sinus bleeding is typically diffuse, dark, and responds well to coagulation current plus a period of catheter traction (the catheter balloon is pulled snugly against the bladder neck to tamponade the prostatic fossa) in the immediate postoperative period. Arterial bleeding is brisker, brighter red, and pulsatile, and requires more definitive point coagulation before closing.
In rare cases of bleeding that cannot be controlled endoscopically, options escalate to prolonged catheter traction, selective angioembolization of prostatic arteries, or (very rarely) open surgical control.
TURP has one of the longest track records and best-characterized outcome and complication profiles of any urologic procedure, with multi-decade follow-up data. Most patients experience substantial, durable improvement in both subjective symptoms and objective flow, at the cost of a well-known set of sexual and urinary side effects that must be discussed preoperatively.
A three-way, 22–24 Fr Foley catheter is placed at the end of the case, balloon inflated (typically 30 mL) and set on gentle traction against the bladder neck for a short period to tamponade the resection bed. Continuous bladder irrigation (CBI) with normal saline runs through the third lumen for roughly 24–48 hours, titrated to keep outflow clear of clots (rosé-to-clear, not gross red).
The catheter is typically removed once irrigation has been clear for several hours and hematuria has settled, generally by hospital day 1–3. A trial of void is then observed before discharge; a small proportion of patients fail this initial trial and require brief recatheterization.
TURP produces some of the most reliable symptom relief in urologic surgery:
• IPSS: mean scores fall from the high teens/20s preoperatively to roughly 6–7 postoperatively — an improvement on the order of 70%, durable at long-term follow-up in most series • Qmax: typically rises from <10–12 mL/s to >20 mL/s • Post-void residual: substantially reduced, often to near-normal • Quality of life: the bother-related IPSS subscore shows some of the largest effect sizes of any BPH intervention, medical or surgical
These gains generally plateau early (by 1–3 months) and are well maintained over years, though a minority of glands regrow adenomatous tissue over time, contributing to the long-term reoperation rate.
Long-term studies (including multi-decade AUA and EAU guideline reviews) consistently rank TURP among the most durable BPH interventions available, which is why — despite the rise of laser and minimally invasive alternatives — it remains the benchmark comparator in essentially every modern BPH device trial.
Key complications and their approximate frequencies, drawn from large contemporary series:
• Retrograde ejaculation: ~65–70% (expected consequence of bladder-neck resection, not a true complication, but must be counseled) • Urethral stricture / bladder neck contracture: ~3–5% • Stress urinary incontinence: <1–2%, related to sphincter injury • Erectile dysfunction: reported in a minority, causation debated versus baseline age-related decline • TUR syndrome: ~2% with monopolar/glycine, near 0% with bipolar/saline • Clot retention / bleeding requiring return to OR: a few percent • Urinary tract infection: variable, reduced by perioperative antibiotics • Reoperation for adenoma regrowth or stricture: roughly 10% cumulative by 5 years
This profile — high symptomatic efficacy balanced against a predictable, mostly manageable complication set — is precisely why TURP has remained a mainstay of BPH surgery for close to a century.